Drug intelligence / Profile preview

BG-2002

Development stage: Preclinical
Lead developer: Guangzhou Bio-gene Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BG-2002 is a chimeric antigen receptor T cell (CAR-T) therapy under development by Guangzhou Bio-gene Technology. It is being investigated for the treatment of neoplasms, specifically solid tumors. As of March 2025, its highest global R&D status is preclinical. The drug's mechanism of action and specific target have not been disclosed publicly. CAR-T therapies are engineered to recognize and attack cancer cells by targeting specific antigens on their surface[1].

Other names: B7H3 CAR-TB-7H3 CAR-TB 7H3 CAR-TB7-H3 CAR-T cell therapyB-7-H3 CAR-T cell therapyB 7-H3 CAR-T cell therapyB7H3-targeted CAR-T cell therapyB-7H3-targeted CAR-T cell therapyB 7H3-targeted CAR-T cell therapy

Targets

B7-H3

Beyond the preview

Go deeper on BG-2002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG-2002.

Explore the full profile